Thomas G. Martin, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
martin_thomas

Clinical Professor of Medicine, Adult Leukemia and Bone Marrow Transplantation Program, and Associate Director, Myeloma Program, UCSF

Phone: (415) 353-2421 (appts)
Box 0324, UCSF
San Francisco, CA 94143-0324

View on UCSF Profiles


Additional Websites


Education

Cornell University, B.A., 1985, Genetics
University of Connecticut School of Medicine, M.D., 1989, Medicine
Harbor-UCLA Medical Center, 1992, Internal Medicine
University of California, San Francisco, 1996, Hematology and Oncology


Professional Experience

  • 1993-1998
    Assistant Adjunct Professor, Hematology and Bone Marrow Transplant, Division of Hematology/Oncology, University of California, San Francisco, CA.
  • 1999-2001
    Assistant Professor of Medicine, Chief, Inpatient BMT Unit, Director, BMT Fellowship Program, Division of Blood and Marrow Transplantation, Department of Medicine, MD Anderson Cancer Center, Houston, TX
  • 2001-2003
    Director, Matched Unrelated Donor Program, Adult Leukemia and Bone Marrow Transplantation, University of California, CA
  • 2001-2003
    Assistant Clinical Professor of Medicine, Adult Leukemia and Bone Marrow Transplantation Program, University of California, San Francisco, CA
  • 2003-2008
    Associate Clinical Professor of Medicine, Adult Leukemia and Bone Marrow Transplantation Program, University of California, San Francisco, CA
  • 2004-Present
    Associate Director, Myeloma Clinic, Adult Ambulatory Care Clinic, University of California, San Francisco, CA.
  • 2006-Present
    Member, Committee on Human Research (CHR), University of California, San Francisco, CA.
  • 2006-Present
    Clinical Director, 11 Long Adult Stem Cell Transplantation
  • 2009-Present
    Clinical Professor of Medicine, Adult Leukemia and Bone Marrow Transplantation Program, University of California, San Francisco, CA

Honors & Awards

  • 1984
    Cornell Tradition Fellow Award
  • 1989
    LANGE Book Award for Scholarship in Internal Medicine, University of Connecticut, Farmington, CT
  • 2003
    Faculty Teaching Award, Division of Hematology/Oncology, University of California, San Francisco, CA

Selected Publications

  1. Stahl E, Martin TG, Praetorius F, Dietz H. Facile and scalable preparation of pure and dense DNA origami solutions. Angew Chem Int Ed Engl. 2014 Nov 17; 53(47):12735-40.
    View on PubMed
  2. Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol. 2014 Jul; 5(3):238-44.
    View on PubMed
  3. Martin TG. Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib. Oncology (Williston Park). 2013 Dec; 27 Suppl 3:4-10.
    View on PubMed
  4. Niesvizky R, Martin TG, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, Wong AF, Lee S, Orlowski RZ, Wang M. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res. 2013 Apr 15; 19(8):2248-56.
    View on PubMed
  5. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10; 366(19):1770-81.
    View on PubMed
  6. Martin TG, Clarke DR, Bowrey DJ. Medical students in theatre: setting the scene. Med Teach. 2012; 34(4):337.
    View on PubMed
  7. Linker C, Damon L, Martin T, Blume K, Forman S, Snyder D, Wolf J, Negrin R. Autologous hematopoietic cell transplantation for high-risk ALL. Bone Marrow Transplant. 2011 Mar; 46(3):460-1.
    View on PubMed
  8. Martin T, Sharma M, Damon L, Kaplan L, Guglielmo BJ, Working M, O'Malley R, Hwang J, Linker C. Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2010 Feb; 12(1):45-50.
    View on PubMed
  9. Damon L, Damon LE, Gaensler K, Kaplan L, Martin T, Rubenstein J, Linker C. Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma. Bone Marrow Transplant. 2008 Nov; 42(10):649-57.
    View on PubMed
  10. de Lima M, Champlin RE, Thall PF, Wang X, Martin TG, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia. 2008 Feb; 22(2):258-64.
    View on PubMed
  11. Lekakis L, Giralt S, Couriel D, Shpall EJ, Hosing C, Khouri IF, Anderlini P, Korbling M, Martin T, Champlin RE, de Lima M. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant. 2006 Sep; 38(6):421-6.
    View on PubMed
  12. Damon L, Rugo H, Tolaney S, Navarro W, Martin T, Ries C, Case D, Ault K, Linker C. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. Biol Blood Marrow Transplant. 2006 Mar; 12(3):316-24.
    View on PubMed
  13. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M, Anderlini P, Kontoyiannis DP, Cohen A, Martin T, Giralt S, Champlin R. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood. 2004 Aug 1; 104(3):649-54.
    View on PubMed
  14. Khorshid O, de Meis E, Martin T, Jones RB, Shpall EJ, Nieto Y, Khouri I, Shahjahan M, Gajewski J, Giralt S, Champlin R, de Lima M. Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant. Leukemia. 2003 Dec; 17(12):2538-40.
    View on PubMed
  15. Gunn N, Damon L, Varosy P, Navarro W, Martin T, Ries C, Linker C. High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant. 2003 Oct; 9(10):643-8.
    View on PubMed
  16. Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C, Andersson BS, Cano P, Shahjahan M, Ippoliti C, Estey EH, McMannis J, Gajewski JL, Champlin RE, de Lima M. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood. 2003 Oct 15; 102(8):3052-9.
    View on PubMed
  17. Thall PF, Inoue LY, Martin TG. Adaptive decision making in a lymphocyte infusion trial. Biometrics. 2002 Sep; 58(3):560-8.
    View on PubMed
  18. Hosing C, Munsell M, Yazji S, Andersson B, Couriel D, de Lima M, Donato M, Gajewski J, Giralt S, K├Ârbling M, Martin T, Ueno NT, Champlin RE, Khouri IF. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol. 2002 Mar; 13(3):450-9.
    View on PubMed
  19. Martin TG, Gajewski JL. Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults. Hematol Oncol Clin North Am. 2001 Feb; 15(1):97-120.
    View on PubMed
  20. Martin TG, Linker CA. Autologous stem cell transplantation for acute lymphocytic leukemia in adults. Hematol Oncol Clin North Am. 2001 Feb; 15(1):121-43.
    View on PubMed

Go to UCSF Profiles, powered by CTSI